Eligible patients will receive escalating doses of 4G7-CARD T-cells paralleling clinical
standard of care with unmanipulated donor lymphocytes. There are 3 intra-patient dose levels
Patients will be followed up regularly during the interventional phase of the study until 12
months post-final 4G7-CARD T-cell infusion. Thereafter patients will be followed up annually
for years 2 and 3.